Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-02-12 Sale |
2024-02-12 8:22 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
2,573 | $11.44 | $29,435 | 451,449 (Direct) |
View |
| 2024-02-02 Sale |
2024-02-05 7:12 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
8,669 | $11.54 | $100,040 | 529,022 (Direct) |
View |
| 2023-10-04 Sale |
2023-10-06 7:18 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
5,482 | $19.5 | $106,926 | 387,691 (Direct) |
View |
| 2023-02-13 Sale |
2023-02-14 7:10 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
7,851 | $20.13 | $158,005 | 392,048 (Direct) |
View |
| 2022-04-04 Sale |
2022-04-05 6:53 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
17,080 | $50.09 | $855,522 | 247,414 (Direct) |
View |
| 2022-02-23 Sale |
2022-02-23 8:12 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
1,913 | $49.1 | $93,921 | 264,494 (Direct) |
View |
| 2021-08-18 Purchase |
2021-08-20 12:59 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
9,611 | $52 | $499,748 | 266,685 (Direct) |
View |
| 2021-07-01 Sale |
2021-07-06 8:01 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
3,083 | $51.27 | $158,054 | 257,074 (Direct) |
View |
| 2021-06-01 Sale |
2021-06-02 8:26 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
3,083 | $54.05 | $166,641 | 260,157 (Direct) |
View |
| 2021-05-03 Sale |
2021-05-05 4:27 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
3,083 | $59.24 | $182,635 | 263,240 (Direct) |
View |
| 2021-04-05 Sale |
2021-04-06 5:46 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
17,107 | $43.39 | $742,323 | 266,323 (Direct) |
View |
| 2021-03-01 Sale |
2021-03-03 4:35 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
3,083 | $41.67 | $128,482 | 283,430 (Direct) |
View |
| 2021-02-01 Sale |
2021-02-03 5:56 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
3,083 | $37.56 | $115,805 | 271,513 (Direct) |
View |
| 2021-01-04 Sale |
2021-01-06 8:24 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
3,083 | $51.91 | $160,034 | 274,596 (Direct) |
View |
| 2020-12-04 Sale |
2020-12-08 8:38 pm |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
13,684 | $52.18 | $714,060 | 277,679 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-01-23 Option Award |
2025-01-27 9:00 pm |
N/A N/A |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
1,672 | $0 | 39,529 (Direct) |
View |
| 2025-01-23 Tax Withholding |
2025-01-27 9:00 pm |
N/A N/A |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
180 | $11.21 | 39,529 (Direct) |
View |
| 2024-10-21 Option Award |
2024-10-23 9:00 pm |
N/A N/A |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
1,613 | $0 | 38,037 (Direct) |
View |
| 2024-09-12 Other |
2024-09-16 9:00 pm |
N/A N/A |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
4,245 | $12.12 | 40,669 (Direct) |
View |
| 2024-09-10 Option Award |
2024-09-12 9:00 pm |
N/A 2034-09-09 |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
44,300 | $0 | 68,563 (Direct) |
View |
| 2024-07-23 Option Award |
2024-07-25 9:00 pm |
N/A N/A |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
1,702 | $0 | 24,263 (Direct) |
View |
| 2024-06-14 Option Award |
2024-06-17 5:37 pm |
N/A 2034-06-14 |
Nautilus Biotechnology Inc. | NAUT | Epperly Melissa B Director |
45,000 | $0 | 45,000 (Direct) |
View |
| 2024-04-24 Option Award |
2024-04-26 9:01 pm |
N/A N/A |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
1,146 | $0 | 22,561 (Direct) |
View |
| 2024-04-24 Tax Withholding |
2024-04-26 9:01 pm |
N/A N/A |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
123 | $10.9 | 22,561 (Direct) |
View |
| 2024-02-01 Option Award |
2024-02-05 7:12 pm |
N/A 2034-01-31 |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
75,000 | $0 | 529,022 (Direct) |
View |
| 2024-01-19 Option Award |
2024-01-23 9:00 pm |
N/A N/A |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
1,207 | $0 | 21,538 (Direct) |
View |
| 2023-10-16 Option Award |
2023-10-18 9:30 pm |
N/A N/A |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
1,226 | $0 | 20,331 (Direct) |
View |
| 2023-09-12 Option Award |
2023-09-14 9:31 pm |
N/A 2033-09-11 |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
44,420 | $0 | 45,700 (Direct) |
View |
| 2023-07-03 Option Award |
2023-07-06 9:30 pm |
N/A N/A |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
1,280 | $0 | 1,280 (Direct) |
View |
| 2023-06-15 Option Award |
2023-06-16 7:52 pm |
N/A 2033-06-15 |
Nautilus Biotechnology Inc. | NAUT | Epperly Melissa B Director |
45,000 | $0 | 45,000 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-13 6:26 pm |
N/A 2033-06-12 |
Kinnate Biopharma Inc. | KNTE | Epperly Melissa B Director |
25,000 | $0 | 25,000 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-01 7:07 pm |
N/A 2033-01-31 |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
250,000 | $0 | 547,942 (Direct) |
View |
| 2022-10-03 Option Award |
2022-10-03 6:42 pm |
N/A N/A |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
50,000 | $0 | 297,543 (Direct) |
View |
| 2022-07-20 Option Award |
2022-07-25 06:06 am |
N/A 2032-07-19 |
Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director |
186,916 | $0 | 186,916 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-16 8:03 pm |
N/A 2032-06-15 |
Nautilus Biotechnology Inc. | NAUT | Epperly Melissa B Director |
86,467 | $0 | 86,467 (Direct) |
View |
| 2022-06-13 Option Award |
2022-06-15 5:00 pm |
N/A 2032-06-13 |
Kinnate Biopharma Inc. | KNTE | Epperly Melissa B Director |
20,250 | $0 | 20,250 (Direct) |
View |
| 2022-02-10 Option Award |
2022-02-14 9:09 pm |
N/A 2032-02-09 |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
54,894 | $0 | 304,896 (Direct) |
View |
| 2021-10-02 Tax Withholding |
2021-10-04 9:16 pm |
N/A N/A |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
17,080 | $67.13 | 250,002 (Direct) |
View |
| 2021-06-11 Option Award |
2021-06-14 7:13 pm |
N/A 2031-06-11 |
Kinnate Biopharma Inc. | KNTE | Epperly Melissa B Director |
20,250 | $0 | 20,250 (Direct) |
View |
Ownership |
2021-06-09 9:41 pm |
N/A 2031-01-31 |
Nautilus Biotechnology Inc. | NAUT | Epperly Melissa B Director |
0 | $0 | 72,561 (Direct) |
View |
| 2021-02-11 Option Award |
2021-02-16 7:05 pm |
N/A 2031-02-10 |
Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer |
60,000 | $0 | 331,513 (Direct) |
View |